In theory, semaglutide could help people fast for longer periods, allowing the body to burn more fat
Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
It's worth noting that up to 40% of patients may feel temporary fatigue when starting GLP-1 medications
U-40 Insulin Syringes: For U-40 insulin (40 units/mL), often used for veterinary purposes or in some countries
SeekPeptides members access comprehensive protocol guidance that incorporates the latest evidence on tirzepatide safety, including thyroid considerations
This session will consider the market as it exists today, and ponder what to expect for GLP-1 legislation, regulation, and litigation over the next 6 months, one year, five years, and beyond.
